BR112023024507A2 - Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central - Google Patents
Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso centralInfo
- Publication number
- BR112023024507A2 BR112023024507A2 BR112023024507A BR112023024507A BR112023024507A2 BR 112023024507 A2 BR112023024507 A2 BR 112023024507A2 BR 112023024507 A BR112023024507 A BR 112023024507A BR 112023024507 A BR112023024507 A BR 112023024507A BR 112023024507 A2 BR112023024507 A2 BR 112023024507A2
- Authority
- BR
- Brazil
- Prior art keywords
- brain
- treating
- growth factor
- nervous system
- central nervous
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 4
- 201000011510 cancer Diseases 0.000 title abstract 4
- 210000003169 central nervous system Anatomy 0.000 title abstract 3
- 210000004556 brain Anatomy 0.000 title abstract 2
- 238000000034 method Methods 0.000 title abstract 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 title 1
- 101800003838 Epidermal growth factor Proteins 0.000 title 1
- 206010027476 Metastases Diseases 0.000 title 1
- 229940116977 epidermal growth factor Drugs 0.000 title 1
- 230000009401 metastasis Effects 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title 1
- 102000001301 EGF receptor Human genes 0.000 abstract 6
- 108060006698 EGF receptor Proteins 0.000 abstract 6
- 150000001875 compounds Chemical class 0.000 abstract 2
- 230000001404 mediated effect Effects 0.000 abstract 2
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 210000000133 brain stem Anatomy 0.000 abstract 1
- 239000000890 drug combination Substances 0.000 abstract 1
- 230000004063 proteosomal degradation Effects 0.000 abstract 1
- 230000034512 ubiquitination Effects 0.000 abstract 1
- 238000010798 ubiquitination Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central. a invenção fornece um tratamento de câncer mediado pelo receptor do fator de crescimento epidérmico mutante (egfr) que sofreu metástase para o cérebro ou outra área do sistema nervoso central com um composto que degrada uma forma mutante de egfr através da ubiquitinação da proteína egfr e subsequente degradação proteassomal. a invenção também fornece combinações de fármacos vantajosas para o tratamento de tal câncer que incluem um composto da presente invenção que degrada uma forma mutante de egfr em combinação com um segundo agente anticâncer.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163193574P | 2021-05-26 | 2021-05-26 | |
| US202163270488P | 2021-10-21 | 2021-10-21 | |
| PCT/US2022/031193 WO2022251539A2 (en) | 2021-05-26 | 2022-05-26 | Egfr degraders to treat cancer metastasis to the brain or cns |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023024507A2 true BR112023024507A2 (pt) | 2024-02-15 |
Family
ID=84230313
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023024507A BR112023024507A2 (pt) | 2021-05-26 | 2022-05-26 | Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240158418A1 (pt) |
| EP (1) | EP4347044A2 (pt) |
| KR (1) | KR20240019099A (pt) |
| AU (1) | AU2022280070A1 (pt) |
| BR (1) | BR112023024507A2 (pt) |
| CA (1) | CA3174207A1 (pt) |
| IL (1) | IL308182A (pt) |
| TW (1) | TW202313025A (pt) |
| WO (1) | WO2022251539A2 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117503737B (zh) * | 2024-01-05 | 2024-04-16 | 成都金瑞基业生物科技有限公司 | 和厚朴酚在制备治疗脂肪肉瘤药物中的用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017164887A1 (en) * | 2016-03-25 | 2017-09-28 | OSI Pharmaceuticals, LLC | Pulse dosing regimen and methods for treatment |
| CR20200625A (es) * | 2018-06-29 | 2021-02-05 | Hoffmann La Roche | Compuestos |
| AU2020405237A1 (en) * | 2019-12-20 | 2022-07-07 | C4 Therapeutics, Inc. | Isoindolinone and indazole compounds for the degradation of EGFR |
-
2022
- 2022-05-26 BR BR112023024507A patent/BR112023024507A2/pt unknown
- 2022-05-26 WO PCT/US2022/031193 patent/WO2022251539A2/en active Application Filing
- 2022-05-26 KR KR1020237041044A patent/KR20240019099A/ko unknown
- 2022-05-26 EP EP22812189.3A patent/EP4347044A2/en active Pending
- 2022-05-26 CA CA3174207A patent/CA3174207A1/en active Pending
- 2022-05-26 TW TW111119753A patent/TW202313025A/zh unknown
- 2022-05-26 IL IL308182A patent/IL308182A/en unknown
- 2022-05-26 AU AU2022280070A patent/AU2022280070A1/en active Pending
-
2023
- 2023-11-21 US US18/516,589 patent/US20240158418A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022251539A3 (en) | 2023-01-05 |
| CA3174207A1 (en) | 2022-12-01 |
| KR20240019099A (ko) | 2024-02-14 |
| TW202313025A (zh) | 2023-04-01 |
| US20240158418A1 (en) | 2024-05-16 |
| IL308182A (en) | 2024-01-01 |
| EP4347044A2 (en) | 2024-04-10 |
| WO2022251539A2 (en) | 2022-12-01 |
| AU2022280070A1 (en) | 2023-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018008069A2 (pt) | métodos de tratamento de doenças neurodegenerati-vas usando terapia gênica para retardar o início e progressão da doença ao mesmo tempo em que fornece proteção cognitiva | |
| BR112019022280A2 (pt) | tratamento de cânceres de her2 positivo | |
| ECSP19043254A (es) | Compuestos con actividad antitumoral contra células cancerosas que tienen mutaciones en el exón 20 de egfr o her2 | |
| WO2018049152A8 (en) | Pyrazolopyrimidine derivatives as hpk1 modulators and uses thereof for the treatment of cancer | |
| BR112019006106A2 (pt) | formulação carregada com canabinoide, processo para preparar a formulação carregada com canabinoide, composições farmacêutica e nutracêutica, e, método de tratamento de um indivíduo sofrendo de uma enfermidade ou um distúrbio. | |
| BR112017020973A2 (pt) | método para tratar câncer em um paciente | |
| BR112016027048A8 (pt) | uso de um composto de fórmula i no tratamento de câncer cerebral e glioblastoma multiforme mgmt positivo | |
| BRPI0510657A (pt) | tratamento com cisplatina e com um inibidor de egfr | |
| BR112023024507A2 (pt) | Método para tratar um câncer mediado por receptor do fator de crescimento epidérmico mutante que sofreu metástase para o cérebro ou sistema nervoso central | |
| WO2019197605A3 (en) | Drug combinations for use in the treatment of ras-mutant cancer | |
| BR112018013063A2 (pt) | combinação terapêutica inibidora de bromodomínio e proteína extra-terminal | |
| BR112021017616A2 (pt) | Conjugado de derivado de anticorpo anti-her2-pirrolobenzodiazepina | |
| BR112018076639A2 (pt) | quimioterapias de combinação | |
| AU2018380132A8 (en) | Tubulin inhibitors | |
| CL2020003306A1 (es) | Composiciones bifuncionales para el tratamiento del cáncer. | |
| PH12020551543A1 (en) | Therapeutic modulators of the reverse mode of atp synthase | |
| BR112022004532A2 (pt) | Processo para tratar drenagem ácida de minas | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| CO2024005352A2 (es) | Composiciones de oligonucleótidos y métodos de estas | |
| BR112018068129A2 (pt) | método para tratamento de um indivíduo que tem ou está sob risco de câncer. | |
| BR112022021956A2 (pt) | Métodos, terapias e usos para o tratamento de câncer | |
| PH12019502096A1 (en) | Pharmaceutical compositions having high drug loadings of medium chain triglycerides and methods related thereto | |
| BRPI0608043A2 (pt) | composição, método que promove a regressão do tumor, linhagem celular, método de identificação de um agente quimioterapêutico, método que promove a apoptose em células do tumor de mama, método de identificação de um agente que aumenta a apoptose em uma célula, uso de um agente e uso do ácido d-ala-l-glu-diaminopimélico | |
| MX2021003527A (es) | Tratamiento de baja intensidad de trastornos hematologicos. | |
| MX2018011760A (es) | Aducto de ciclodextrina-panobinostat. |